OREXO PATENT FOR RAPID DELIVERY ISSUED IN EU.Orexo Pharmaceuticals has announced that a European Patent has been granted for one of their technology platforms, the sublingual sublingual /sub·lin·gual/ (-ling´gwal) hypoglossal; beneath the tongue. sub·lin·gual adj. Abbr. SL Below or beneath the tongue; hypoglossal. tablet technology. Several of the company's product projects are based on this technology. The technology enables rapid absorption of pharmaceutical compounds and can in certain cases substitute for injections. Orexo Pharmaceuticals product development strategy requires a strong and active patent strategy. Innovative drug delivery based on well-known pharmacological Pharmacological Referring to therapy that relies on drugs. Mentioned in: Pain Management pharmacological, pharmacologic pertaining to pharmacology. substances enables the company to bring patented, innovative products to market much faster compared to traditional drug development. One of the company's most advanced projects, now in preparation for phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA studies, will benefit greatly from this approval. The product Rapinyl, developed for rapid relief of cancer breakthrough pain, is based on the technology for fast dissolving sublingual tablets. The Japanese marketing rights for Rapinyl were licensed to Kyowa Hakko Kogyo Co. Ltd in January 2003 and negotiations for the marketing rights in the EU and US are ongoing. The formulation technology behind the approved patent is well suited for pharmaceuticals where fast action of onset is needed. This can be exemplified by the company[acute accent acute accent n. A mark (´) indicating: a. that a vowel is close or tense, as é in French été. b. that a vowel or syllable has a high or rising pitch, as in Chinese or Ancient Greek. c. ]s second product based on the technology, a tablet for treatment of insomnia insomnia, abnormal wakefulness or inability to sleep. The condition may result from illness or physical discomfort, or it may be caused by stimulants such as coffee or drugs. However, frequently some psychological factor, such as worry or tension, is the cause. , where the clinical trial program starts during spring 2004. The patent for the sublingual tablet technology is already approved in several other markets among those Japan, Australia and New Zealand New Zealand (zē`lənd), island country (2005 est. pop. 4,035,000), 104,454 sq mi (270,534 sq km), in the S Pacific Ocean, over 1,000 mi (1,600 km) SE of Australia. The capital is Wellington; the largest city and leading port is Auckland. . Orexo AB (publ) is a Swedish pharmaceutical company established in 1995 based in Uppsala. Orexo develops, documents and registers patented pharmaceutical products based on innovative and proprietary drug formulations. This is carried out through in-house development, licensing or co-development with partners. For more information, visit http://www.orexo.se. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion